Company intelligence / Profile preview
BiomX
Gaithersburg, Maryland, USA
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
BiomX is advancing BX004, a phage cocktail therapy, in Phase 2b trials for cystic fibrosis patients with Pseudomonas aeruginosa infections, reporting recent positive clinical updates. Their pipeline also includes programs targeting chronic wounds and atopic dermatitis in earlier stages.
- Therapeutic areas
- Infectious DiseasesDermatologyPulmonology
- Modalities
- Phage therapyLive biotherapeutic product therapy
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on BiomX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiomX.